Early research (Phase 1)Ended earlyNCT05289492What this trial is testingStudy of Novel Regimens in Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma iTeos Therapeutics 16
Very early researchLooking for participantsNCT04657861What this trial is testingAPRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma in RelapseMultiple Myeloma, Refractory Zhejiang University 36
Early research (Phase 1)Study completedNCT04322292What this trial is testingBCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaWho this might be right forMultiple Myeloma Institute of Hematology & Blood Diseases Hospital, China 9
Early research (Phase 1)Ended earlyNCT03582033What this trial is testingA Safety Study of SEA-BCMA in Patients With Multiple MyelomaWho this might be right forMultiple Myeloma Seagen Inc. 83
Early research (Phase 1)Study completedNCT02519452What this trial is testingDaratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Janssen Research & Development, LLC 120
Testing effectiveness (Phase 2)Study completedNCT02963493What this trial is testingMelphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Oncopeptides AB 157
Testing effectiveness (Phase 2)Ended earlyNCT00017069What this trial is testingArsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple MyelomaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm CTI BioPharma
Early research (Phase 1)Study completedNCT02561962What this trial is testingStudy in Subjects With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Amgen 42
Early research (Phase 1)Study completedNCT01122875What this trial is testingThe Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple MyelomaWho this might be right forMultiple Myeloma Genentech, Inc. 14
Large-scale testing (Phase 3)Not Yet RecruitingNCT06742138What this trial is testingTo Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple MyelomaWho this might be right forMultiple Myeloma Qilu Pharmaceutical Co., Ltd. 284
Not applicableApproved For MarketingNCT05463939What this trial is testingTeclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma PatientsWho this might be right forRelapsed or Refractory Multiple Myeloma Janssen Research & Development, LLC
Large-scale testing (Phase 3)Study completedNCT03952091What this trial is testingTJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma in RelapseRefractory Multiple Myeloma TJ Biopharma Co., Ltd. 289
Testing effectiveness (Phase 2)Study completedNCT00006013What this trial is testingSU5416 in Treating Patients With Refractory or Relapsed Multiple MyelomaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm Fox Chase Cancer Center 21
Early research (Phase 1)Study completedNCT02332850What this trial is testingPhase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Thomas Martin, MD 83
Early research (Phase 1)Study completedNCT00932698What this trial is testingStudy of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple MyelomaWho this might be right forRelapsed and Refractory Multiple Myeloma Millennium Pharmaceuticals, Inc. 60
Large-scale testing (Phase 3)Looking for participantsNCT07222761What this trial is testingCompare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Who this might be right forRelapsed and/or Refractory Multiple Myeloma (RRMM) Regeneron Pharmaceuticals 915
Early research (Phase 1)Study completedNCT00545519What this trial is testingA Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple MyelomaWho this might be right forRelapsed Or Refractory Multiple Myeloma Washington University School of Medicine 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT03989414What this trial is testingDetermine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Who this might be right forMultiple Myeloma Celgene 424
Testing effectiveness (Phase 2)Ended earlyNCT06351644What this trial is testingON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaWho this might be right forRelapsed and/or Refractory Multiple Myeloma Adriana Rossi 2
Testing effectiveness (Phase 2)UnknownNCT04674514What this trial is testingAPG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Ascentage Pharma Group Inc. 48